1. <scp>R‐MACLO‐IVAM</scp> regimen followed by maintenance therapy induces durable remissions in untreated mantle cell lymphoma ‐ Long term follow up results
- Author
-
Isildinha M. Reis, Izidore S. Lossos, Eduardo Edelman Saul, Joseph D. Rosenblatt, Alvaro J. Alencar, Juan Pablo Alderuccio, and Sunil Iyer
- Subjects
Adult ,Male ,medicine.medical_specialty ,Adolescent ,Kaplan-Meier Estimate ,Lymphoma, Mantle-Cell ,Gastroenterology ,Disease-Free Survival ,Maintenance Chemotherapy ,Young Adult ,Maintenance therapy ,Median follow-up ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Ifosfamide ,Prospective Studies ,Adverse effect ,Cyclophosphamide ,Aged ,Etoposide ,Aged, 80 and over ,Not evaluated ,business.industry ,Remission Induction ,Cytarabine ,Hematology ,Middle Aged ,medicine.disease ,Progression-Free Survival ,Thalidomide ,Regimen ,Methotrexate ,Doxorubicin ,Vincristine ,Female ,Mantle cell lymphoma ,Rituximab ,business ,Follow-Up Studies ,medicine.drug - Abstract
We present long-term combined results of two clinical trials implementing R-MACLO-IVAM induction followed by thalidomide or rituximab maintenance in 44 patients with untreated mantle cell lymphoma (MCL). The first 22 patients (UM-MCL1 ClinicalTrials.gov identifier NCT00450801) received maintenance with thalidomide (200 mg daily until relapse/intolerable toxicity) and a subsequent cohort of 22 patients (UM-MCL2 ClinicalTrials.gov identifier NCT00878254) received rituximab (375 mg/m2 IV weekly × 4, repeated every 6 months for 3 years). Considering all 44 patients, 41 (93.2%) achieved complete response (CR), two (4.5%) partial response (PR), and one (2.3%) was not evaluated for response. With a median follow up of 7.2 years (range < 1 month to 16 years), the 5-year progression-free survival (PFS) was 55.6% (95% CI: 38.9%-69.4%) and median PFS 7.9 years (95% CI: 3.7-11 years). The 5-year OS was 83.3% (95% CI: 68.1%-91.7%) and median OS was not reached. Patients with blastic variant (n = 6) had a 5-year PFS and OS of 20.8% and 60%, respectively. Myelosuppression was the most common adverse event during immunochemotherapy. Long-term treatment-related mortality was 6.8%. Note, R-MACLO-IVAM followed by maintenance therapy is an effective regimen to induce long-term remission in MCL without need for consolidation with ASCT.
- Published
- 2021